The government has announced that people who have participated in a trial of COVID vaccines that have not yet been approved should be offered two additional doses of the Pfizer jab, to allow them to travel internationally Can you
The policy applies to more than 21,000 individuals, about 15,000 of whom received the Novavax vaccine last summer as part of a large-scale trial, and they were required to visit those countries. will provide status that tests do not recognize vaccination.
Additional doses will initially be given to people who have tested the Novavax jab, which has been found to be safe and effective but has not yet been approved by the UK drug regulator, which is seeking to receive other vaccines still under review. extended to the people.
These individuals have found themselves in limbo over the past year – unable to get an approved jab during the UK rollout and, as a result, banned from countries that only admit individuals who have received globally recognized vaccines. has been immunized.
But under new guidance issued by the government, these people will now be able to receive two doses of the Pfizer vaccine – separated by the usual eight-week interval.
England’s Deputy Chief Medical Officer Professor Jonathan Van-Tam said: “The measures we have taken will allow UK COVID-19 vaccine trial participants to travel abroad freely after having additional vaccinations.”
“Those volunteers now have the flexibility to make decisions for themselves so that they can, for example, visit loved ones abroad.”
The UK recognizes people who participated in COVID-19 vaccine clinical trials were fully vaccinated; However, most other countries do not do this.
It is understood that the government is ready to inspire other countries to change their policy on this and make it easier for clinical trialists to travel around the world.
“If more countries around the world had allowed UK volunteers to travel abroad to enjoy fully immunized status, these measures would not have been necessary,” Prof Van-Tam said.
There have been trials globally on receiving a third dose of the vaccine, but not a fourth. Senior health officials do not anticipate any complications to arise, and provide 1-to-1 clinical consultations for clinical trial takers to address their questions and concerns about receiving additional doses. Will be done.
In January, Novavax posted positive results for its UK trial, but it has yet to file for approval from the Medicines and Healthcare products Regulatory Agency (MHRA), saying it will do so in the next “few months”. intends to.
Credit: www.independent.co.uk /